Skip to main content

Table 7 Impact of dossier evidence on DERP reports by clinical category

From: A study of the value of requesting information from drug manufacturers for systematic reviews; 9 years of experience from the drug effectiveness review project

Clinical area Included from dossiers Used qualitatively Used in MA Gap Confirms Changes
All 160 142(89%) 26 (16%) 72 (45%) 66 (41%) 67 (42%)
 Cardiovascular 3 3(100%) 0 0 3(100%) 0
 Dermatology 10 10 (100%) 6(60%) 3(30%) 10 (100%) 5(50%)
 Endocrinology 16 11(69%) 4(25%) 8(50%) 9(56%) 9(56%)
 Gastrointestinal 22 21(95%) 1(5%) 12(55%) 6(27%) 6(27%)
 Hepatitis 17 15 (88%) 2(12%) 8(47%) 7(41%) 5(29%)
 Pain/neurology 17 12(71%) 5(29%) 4(24%) 11(65%) 4(24%)
 Psychiatry 54 49 (91%) 6(11%) 29(54%) 15(28%) 31(57%)
 Respiratory 20 19(95%) 1(5%) 6(30%) 5(25%) 6(30%)
Studies 123      
 Cardiovascular 0  
 Dermatology 6 6 (100%) 5 (83%) 2 (33%) 6 (100%) 4 (67%)
 Endocrinology 12 8 (67%) 4 (33%) 6 (50%) 7 (58%) 7 (58%)
 Gastrointestinal 21 20 (95%) 1 (5%) 11 (52%) 6 (29%) 6 (6%)
 Hepatitis 8 6 (75%) 2 (25%) 5 (63%) 2 (25%) 5 (63%)
 Neurology/pain 11 6 (55%) 5 (45%) 1 (9%) 7 (64%) 2 (18%)
 Psychiatry 46 41 (89%) 6 (13%) 26 (57%) 14 (30%) 27 (59%)
 Respiratory 19 18 (95%) 1(5%) 6 (32%) 5 (26%) 5 (26%)
Supplemental evidence 37      
 Cardiovascular 3 3 (100%) 0 0 3(100%) 0
 Dermatology 4 4(100%) 2(50%) 1 (25%) 4(100%) 1 (25%)
 Endocrinology 4 4(100%) 0 2 (50%) 2(50%) 2 (50%)
 Gastrointestinal 1 1 (100%) 0 1(100%) 0 0
 Hepatitis 9 9 (100%) 0 3 (33%) 5 (56%) 0
 Neurology/pain 6 6 (100%) 0 3(50%) 4 (67%) 1 (17%)
 Psychiatry 8 8 (100%) 0 4 (50%) 1 (13%) 4 (50%)
 Respiratory 2 2 (100%) 0 1 (50%) 0 1(50%)
Published studies 95      
 Cardiovascular 3 3 (100%) 0 0 3 (100%) 0
 Dermatology 10 10 (100%) 7 (70%) 3 (30%) 10 (100%) 5 (50%)
 Endocrinology 15 10 (67%) 4 (27%) 8 (53%) 8 (53%) 9 (60%)
 Gastrointestinal 22 20 (91%) 1 (5%) 12 (55%) 6 (27%) 6 (27%)
 Hepatitis 7 5 (71%) 2 (29%) 4 (57%) 3(43%) 3 (43%)
 Neurology 5 4 (80%) 1 (20%) 2 (40%) 2 (40%) 3 (30%)
 Psychiatry 24 21 (88%) 2 (8%) 10 (42%) 8 (33%) 8 (33%)
 Respiratory 9 8 (89%) 1 (11%) 4 (44%) 3 (33%) 3 (33%)
Unpublished evidence 65      
 Cardiovascular 0  
 Dermatology 0
 Endocrinology 1 1 (100%) 0 0 1(100%) 0
 Gastrointestinal 0
 Hepatitis 10 10 (100%) 0 4 (40%) 4 (40%) 2 (20%)
 Neurology 12 8 (67%) 4 (33%) 2 (17%) 9 (75%) 1 (8%)
 Psychiatry 30 27 (90%) 4 (13%) 20 (67%) 7 (23%) 23 (77%)
 Respiratory 12 12 (100%) 0 3 (25%) 2 (17%) 3 (25%)
  1. MA meta-analyses